Actavis to spend $66B on Allergan |

Actavis to spend $66B on Allergan

The Associated Press

Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced this year, plans to stay committed to developing products.

CEO Brent Saunders said Monday that the combined company will have more than two dozen products in late-stage clinical testing, which is usually the last and most expensive development phase, and it will work to support research.

“It is the lifeblood of our company,” he told analysts.

Actavis and the company it outbid for Allergan, Valeant Pharmaceuticals, have grown rapidly in recent years through multibillion-dollar acquisitions of other drugmakers. But experts say developing products internally is the preferred method for revenue growth if — and it’s a huge ‘if’ — enough of that research is successful.

“It’s also really risky,” said Erik Gordon, a professor at the University of Michigan’s Ross School of Business who follows the pharmaceutical industry.

Allergan spent months fending off overtures from Valeant, in part because it thought the Canadian drugmaker would gut its research funding. The Irvine, Calif., company complained that Valeant’s $53 billion bid was too low. Valeant Pharmaceuticals International Inc. partnered with the hedge fund and Allergan shareholder Pershing Square Capital Management on the bid.

Monday, Actavis announced an offer of about $219 in cash and stock for each Allergan share that has the support of both companies.

Valeant said separately that the Actavis bid is a price it “cannot justify to its own shareholders.”

The deal arises months after Actavis polished off a $28 billion purchase of Forest Laboratories. Last year, it bought Ireland’s Warner Chilcott for $8.5 billion and moved its headquarters to Dublin from Parsippany, N.J. That arrived a year after it merged with generic drugmaker Watson Pharmaceuticals.

Actavis PLC announced another deal update on Monday. It completed its offer to buy all outstanding shares of Durata Therapeutics Inc. in a deal worth about $675 million.

Other drugmakers, such as Merck & Co. and Novartis, have announced multibillion-dollar transactions this year.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.